The benefits of second-line CAR-T cell therapy

Frederick Locke, MD, Moffitt Cancer Center, Tampa, FL, discusses whether chimeric antigen receptor (CAR) T-cell therapies should be moved into earlier lines of treatment. Data from the Phase III ZUMA-7 trial (NCT03391466), which assessed axicabtagene ciloleucel in patients with relapsed/refractory diffuse large B-cell lymphoma, indicated that patients greatly benefited from CAR-T cell therapy as second-line therapy. Dr Locke additionally highlights the need for early referral to treatment, which is achievable with CAR-T cell therapies due to their quick manufacturing times. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.